Uromitexan

Uromitexan

mesna

Manufacturer:

Baxter Healthcare

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Mesna
Indications/Uses
Prevention of urotoxic effects of oxazaphosphorines.
Dosage/Direction for Use
Adult IV inj Per dose: 20% of dose of oxazaphosphorine, administered at time zero (time of administration of oxazaphosphorine) repeated after 4 & 8 hr. W/ a continuous oxazaphosphorine infusion: 20% of the oxazaphosphorine dose given as a bolus inj at time zero, followed by a continuous infusion of Uromitexan of up to 100% of the initial oxazaphosphorine dose. Continue infusion for a further 6-12 hr after the end of the oxazaphosphorine administration.
Special Precautions
Protective effect applies only to the urinary tract.
Adverse Reactions
GI effects, headache, malaise, skin rash. Allergic symptoms (rare).
ATC Classification
V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Presentation/Packing
Form
Uromitexan amp 400 mg/4 mL
Packing/Price
15 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in